Clinical Trials in Italy / NCT07082725
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725 · tracked via the Priya Life Science Italy tracker
Condition(s) studied
Niemann-Pick Type C Disease
Investigational drug(s) / intervention(s)
Nizubaglustat →Placebo
Nizubaglustat: AZ-3102
Placebo: Matching placebo
Study summary
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease
Eligibility
Inclusion Criteria:
* Signed informed consent
* Confirmed diagnosis of NPC disease
* Patient is unable or unwilling to take miglustat, or is, in the opinion of the investigator, unsatisfactorily treated with miglustat
* Male and female participants aged 4 years and older at the time of informed consent
* Onset of neurological symptoms from 2 to 15 years
* Disability level at Baseline: Ataxic disturbances with a total SARA score of ≥3 and ≤30 at Baseline
* Female of childbearing potential who are sexually active willing to follow the contraceptive guidance
* Male participants with a female partner of childbearing potential willing to follow the contraceptive guidance
Exclusion Criteria:
* A history of medical conditions other than NPC disease that, in the opinion of the Principal Investigator, would confound scientific rigor or the interpretation of results
* Body weight of \<10 kg
* The presence of another neurologic disease
* The presence of moderate or severe hepatic impairment
* The presence of moderate or severe renal impairment
* Platelet count of \<100x10\^9/L
* The dose of any anti-epileptic treatment(s) was not stable (required a change in dose within the previous 3 months) and/or a new anti-epileptic treatment (drug or procedure) was prescribed in the month before Baseline
* Prior use of an investigational drug within the 3 months before Screening; or prior participation in a clinical study involving gene therapy or stem cell transplantation within 2 years prior to Screening
* A positive serum pregnancy test (for women of childbearing potential)
* Current treatment with miglustat, provided the patient has been using the recommended dose for most of the past 12 months AND is, in the opinion of the investigator, satisfactorily treated with miglustat. Any participants receiving miglustat are required to undergo a 1-month washout period before starting study medication
Primary outcome measure(s)
- Change from baseline in total Scale for the Assessment and Rating of Ataxia (SARA) score — Baseline to month 18
Total SARA comprises eight categories with a cumulative score ranging from 0 (no ataxia) to 40 (most severe ataxia) - Change from baseline in functional SARA score — Baseline to month 18
Functional SARA uses an abbreviated scale that scores 0 to 16, with higher scores indicating more severe impairment
Trial sites (34)
| Facility | City | Region | Status |
|---|---|---|---|
| UCSF Children's Hospital and Research Center at Oakland | Oakland | California | Recruiting |
| University of Minnesota Medical School | Minneapolis | Minnesota | Recruiting |
| Mayo Clinic Children's Center - PIN | Rochester | Minnesota | Recruiting |
| Children's Medical Center Dallas | Dallas | Texas | Recruiting |
| Lysosomal Rare Disorders Research and Treatment Center | Fairfax | Virginia | Recruiting |
| Hospital de Niños de La Santisima Trinidad | Córdoba | Córdoba Province | Recruiting |
| Women's and Children's Hospital | North Adelaide | South Australia | Recruiting |
| Royal Melbourne Hospital | Parkville | Victoria | Recruiting |
| Royal Children's Hospital Melbourne - PIN | Parkville | Victoria | Recruiting |
| Instituto Fernandes Figueira | Rio de Janeiro | Rio de Janeiro | Recruiting |
| Hospital de Clinicas de Porto Alegre (HCPA) - PPDS | Porto Alegre | Rio Grande do Sul | Recruiting |
| Hospital Pequeno Principe | Curitiba | Brazil | Not Yet Recruiting |
| M.A.G.I.C. Clinic Ltd. Metabolics and Genetics in Calgary | Calgary | Alberta | Recruiting |
| University of Alberta Medical Genetics Clinic | Edmonton | Alberta | Not Yet Recruiting |
| Centre Hospitalier de l'Universite de Montreal-1000 rue Saint-Denis | Montreal | Quebec | Not Yet Recruiting |
| SphinCS GmbH | Höchheim | Germany | Recruiting |
| Amrita Institute of Medical Sciences and Research Centre | Ernākulam | Kerala | Recruiting |
| All India Institute of Medical Sciences (AIIMS) - New Delhi | New Delhi | National Capital Territory of Delhi | Recruiting |
| JK Lone Hospital | Jaipur | Rajasthan | Recruiting |
| Christian Medical College and Hospital | Vellore | Tamil Nadu | Recruiting |
| Fondazione IRCCS Istituto Neurologico Carlo Besta | Milan | Italy | Recruiting |
| Hospital Universitario Dr. Jose Eleuterio González | Monterrey | Nuevo León | Not Yet Recruiting |
| Centenario Hospital Miguel Hidalgo | Aguascalientes | Mexico | Not Yet Recruiting |
| The Children's Hospital & the University of Child Health Lahore | Lahore | Punjab Province | Not Yet Recruiting |
| ULS de Santo António, EPE - Centro Materno Infantil Norte | Porto | Porto District | Recruiting |
| Hospital Universitario Vall d'Hebron - PPDS | Barcelona | Barcelona | Recruiting |
| Hospital Infantil Universitario Niño Jesus - PIN | Madrid | Madrid | Recruiting |
| Inselspital - Universitätsspital Bern | Bern | Canton of Bern | Recruiting |
| Cukurova Universitesi Balcali Hastanesi Saglik Uygulama ve Arastirma Merkezi | Adana | Adana | Recruiting |
| Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi | Çankaya | Ankara | Recruiting |
| Ege Universitesi Tip Fakultesi | Bornova | İzmir | Recruiting |
| Great Ormond Street Hospital | London | London | Recruiting |
| University College London Hospitals (UCLH) | London | Middlesex | Not Yet Recruiting |
| Royal Manchester Children's Hospital | Manchester | United Kingdom | Not Yet Recruiting |
More Azafaros B.V. trials in Italy
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07082725 on ClinicalTrials.gov ↗ ← All trials in Italy